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ABSTRACT
The adipocytokines and insulin-like growth factor 1 (IGF-1) are involved in insulin resistance, the
cardiometabolic syndrome, and atherosclerosis. Therefore, investigating the relationship between cir-
culating levels of the novel adipocytokines and IGF-1 is worthwhile. The correlation between IGF-1,
visfatin, and omentin-1 has not been adequately investigated. In a population-based study, 324 post-
menopausal women were randomly selected. Circulating IGF-1, visfatin, omentin-1, adiponectin, and
high-sensitivity C-reactive protein (hs-CRP) levels were measured with the highly specific enzyme-linked
immunosorbent assay method. In multiple regression analyses adjusted for alkaline phosphatase,
osteocalcin, and hs-CRP, circulating IGF-1 was significantly correlated with visfatin levels (standardized
β coefficient [β] = 0.13, partial correlation coefficient [r] = 0.12, p = 0.028). The significant positive
correlation between serum IGF-1 and visfatin levels remained after additional adjustments for age and
BMI (β = 0.12, r = 0.12, p = 0.025), metabolic syndrome (β = 0.13, r = 0.12, p = 0.021), and type 2 diabetes
mellitus (β= 0.13, r = 0.12, p = 0.026). No significant correlations were found between IGF-1, adiponectin,
and omentin-1. There is a significant correlation between serum IGF-1 and visfatin levels in postmeno-
pausalwomenbeyondmetabolic syndrome, type 2diabetes, bone formationmarkers, andhs-CRP levels.
The observed correlation between higher circulating IGF-1 and the higher visfatin levels might be a
physiological compensation and adaptation to protect against visfatin-induced proinflammatory effects.
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Introduction
The adipocytokines expressed specifically and abun-
dantly in adipose tissue influencemany organ systems
with important systemic interactions. Over the past
few years, adipocytokines have been the focus of
research on diabetes, obesity, and cardiovascular
diseases because several classic and novel
adipocytokines regulate metabolism and insulin resis-
tance and contribute to chronic inflammation
associated with metabolic syndrome and cardiometa-
bolic disorders (1). Some adipocytokines such as adi-
ponectin and omentin-1 are cardioprotective and
counteract chronic low-grade inflammation and
endothelial dysfunction (2).
Adiponectin has attracted much attention
due to its antidiabetic, anti-inflammatory, and
anti-atherogenic properties (3). Adiponectin is
negatively correlated with various obesity
measures, as well as with insulin-resistance
indices (4). Omentin-1 enhances insulin action
and Akt phosphorylation (5), and omentin-1 is
downregulated by elevated insulin and glucose
levels (6). Omentin-1 also is inversely related to
obesity and insulin resistance and positivity
correlated with adiponectin levels (7).
Omentin-1 levels were lower in patients with
metabolic syndrome than in controls (8).
However, several adipocytokines such as leptin,
resistin, and visfatin may contribute in the pathogen-
esis of atherosclerosis (2). Visfatin (nicotinamide
phosphoribosyltransferase (NAMPT) or pre-B-cell
colony-enhancing factor 1) is secreted abundantly by
the visceral fat in humans and mice and mimics the
action of insulin (9). In vitro and in vivo studies have
shown that visfatin may be involved in the
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development and progression of atherosclerosis
through cell proliferation, monocyte/macrophage
activation and recruitment, vascular smooth muscle
inflammation, and plaque destabilization (10).
Human studies have shown inconsistent and conflict-
ing results regarding associations between visfatin and
the insulin-mimetic effect, insulin resistance, beta cell
function impairment, adiposity, subcutaneous versus
visceral fat distribution, and diabetes (11–13).
Insulin-like growth factor 1 (IGF-1) is a 7.6 kDa 70-
amino-acid peptide, which is primarily synthesized in
the liver in response to growth hormone.
Accumulating evidence supports the regulatory roles
of IGF-1 in proliferation, differentiation, metabolism,
senescence, and apoptosis (14). Themitogen-activated
protein kinase (MAPK) cascade and the phosphatidy-
linositol 3’-kinase (PI3K) pathway are involved in the
mitogenic action and the metabolic and antiapoptotic
signals of IGF-1 (15). In humans, an inverse associa-
tion between circulating IGF-1 levels and athero-
sclerotic cardiovascular diseases as well as the
prevalence of metabolic syndrome and its compo-
nents has been observed (15–18).
Since the adipocytokines and IGF-1 are involved in
insulin resistance, the cardiometabolic syndrome, and
atherosclerosis (1–18), investigating the relationship
between the circulating levels of novel adipocytokines
and IGF-1 is worthwhile. This knowledge might pro-
vide useful insights into the pathophysiology of ather-
osclerosis and cardiometabolic risk.
There is little evidence regarding IGF-1 in rela-
tion to adiponectin levels, and the evidence is
controversial. Positive correlation in obese nondia-
betic women (19), negative association in type 2
diabetes mellitus (20), and no consistent associa-
tion in postmenopausal women (21) were found
between adiponectin and IGF-1 levels. The GH/
IGF-1 cascade in relation to visfatin levels was
investigated in patients with HIV (22), growth
hormone deficiency (23), active acromegaly (24),
retinopathy of prematurity (25), in relation to pre-
natal growth (26), and in human articular chon-
drocytes (27). However, whether or not serum
IGF-1 levels are associated with omentin-1 has
not yet been investigated. In the current study,
we investigated the correlation between IGF-1
and adiponectin, omentin-1, and visfatin in a com-
munity-based study among postmenopausal
Iranian women. To our knowledge, this is the
first population-based study that investigated the
association among circulating IGF-1 concentra-
tions, omentin-1, and visfatin levels.
Methods
Community sampling and physical examinations
The study design has been described previously (28).
Briefly, the participants in the present study consisted
of an age-stratified randomsample of postmenopausal
women, who participated in the extension of the
Iranian Multicentral Osteoporosis Study (IMOS).
The purpose of IMOS was to determine peak bone
mass in healthy men and women. A total of 5201
participants were recruited from five major cities
throughout the country in IMOS. According to the
study protocol, 120 healthy men and women, aged
20–69 years in each age decade in every city should be
randomly selected. We extended the study in order to
include more postmenopausal women to determine
postmenopausal osteoporosis in Bushehr (one of the
five major cities). A total of 406 postmenopausal
women were randomly selected from 13 clusters in
the port city of Bushehr. However, 324 of the selected
postmenopausal women had adequate aliquot of sera
to measure the adipocytokines and IGF-1 levels.
All of the women, who were community dwelling
and ambulatory, were asked to fast and to come to the
survey center between 7:30 and 9:30 a.m. On arrival at
the survey site, information regarding the participants’
age, sex, marital status, and education was recorded.
Further questions were asked about their smoking
status, use of postmenopausal hormone replacement
therapy, and any drugs taken for angina, as well as
whether they had any history of hypertension, dia-
betes, or dyslipidemia.
The participants’ blood pressurewas assessed twice,
via the right arm, after a 15-minute rest in the sitting
seated position. A standard mercury sphygmoman-
ometer was used. The women’s heights and weights
were measured using a stadiometer (heavy outer gar-
ments and shoes were removed first) and their body
mass indexes (BMIs) were calculated.
Laboratory measurements
Fasting blood samples were obtained from April 4
to September 22, 2006. Sera were then aliquoted
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into microtubules and stored at –80°C until ana-
lyzed. The analyses for glucose levels and lipid
profile were carried out at the Persian Gulf
Health Research Center on the day of blood col-
lection using a Selectra 2 autoanalyzer (Vital
Scientific, Spankeren, Netherlands). Glucose was
assayed by the enzymatic (glucose oxidase) colori-
metric method using a commercial kit (Pars
Azmun Inc., Tehran, Iran). Serum total cholesterol
and HDL cholesterol were measured using a cho-
lesterol oxidase phenol aminoantipyrine, and tri-
glycerides were measured using a glycerol-3
phosphate oxidase phenol aminoantipyrine enzy-
matic method. Serum LDL cholesterol was calcu-
lated using the Friedewald formula; LDL
cholesterol was not calculated when the triglycer-
ide concentration was >400 mg/dl.
All assays were performed according to the
manufacturer’s instruction; IGF-I levels were mea-
sured by DRG IGF-I 600 Enzyme Immunoassay
Kit (DRG Instruments G mbH, Germany), and
this kit is a solid-phase ELISA, based on the prin-
ciple of competitive binding; osteocalcin was mea-
sured by N-MID Osteocalcin ELISA (Nordic
Bioscience Diagnostics A/S, Herlev, Denmark),
and this kit is based upon the application of two
highly specific monoclonal antibodies against
human osteocalcin; CrossLaps was measured by
enzyme-linked immunosorbent assay (Nordic
Bioscience Diagnostics A/S, Herlev, Denmark),
the Serum CrossLaps® ELISA is based on two
highly specific monoclonal antibodies against the
amino acid sequence of EKAHD-β-GGR, where
the aspartic acid residue (D) is β-isomerized; alka-
line phosphatase was measured by spectrophoto-
metry using p-nitrophenylphosphate as substrate
(Pars Azemon, Tehran, Iran); adiponectin was
measured commercially by an available ELISA
kits (Cat. No. AG-45A-0001EK-KI01; AdipoGen,
Incheon, Korea), this assay is a sandwich Enzyme
Linked-Immunosorbent Assay (ELISA) for quan-
titative determination of human adiponectin in
biological fluids; omentin-1 was measured by
omentin-1 (human) detection (ELISA kit [intelec-
tin-1 (human) ELISA kit, Apotech Corporation,
Switzerland]), the antibodies used in this kit are
specific to the measurement of natural and recom-
binant human omentin-1; visfatin was measured
commercially (Cat. No. V0523EK) by an available
enzyme-linked immunosorbent assay kit
(AdipoGen, Seoul, Korea), this assay is a sandwich
ELISA for quantitative determination of human
Nampt in biological fluids; and C-reactive protein
(CRP) was measured by CRP HS ELISA (DRG
International), a highly sensitive (hs) CRP assay,
the assay system utilizes a unique monoclonal
antibody directed against a distinct antigenic
determinant on the CRP molecule.
Definitions
Using the American Diabetes Association’s cri-
teria, the existence of diabetes in a patient was
defined either by a fasting plasma glucose level
≥126 mg/dL or by the use of antidiabetic measures
(29). The metabolic syndrome was diagnosed with
the criteria indicated by the NCEP-ATP III (30).
Statistical analysis
The distribution of the data was controlled using
the Kolmogorov–Smirnov test. A two-tailed t-test
was used to compare the mean values across
groups. We found that log transformation of adi-
ponectin, visfatin, omentin-1, CrossLaps, osteocal-
cin, and IGF-1 gave a better fit to a Gaussian
distribution. The geometric mean for those bio-
chemical variables was defined as the arithmetic
mean of the log-transformed data ±SD, converted
back to a base 10 number.
Pearson’s correlation analysis was used to study
the relationships between the log-transformed
IGF-1 values and the anthropometric and bio-
chemical variables. Partial correlation analysis
was performed to assess the association between
IGF-1 measurements and biochemical variables,
with adjustment for age and weight.
Multiple linear regression models were used to
assess the association between IGF-1 (as the
dependent variable) and adipocytokines. The bio-
chemical variables (alkaline phosphatase, osteocal-
cin, and hs-CRP) that showed significant
correlations with IGF-1 levels were entered simul-
taneously in the standard linear regression models.
The metabolic syndrome, type 2 diabetes mellitus,
and BMI were considered as covariates in different
multiple regression models.
ENDOCRINE RESEARCH 3
A p value of less than 0.05 was accepted as signifi-
cant. All statistical analyses were performed using
PASWStatisticsGradPack 18 (SPSS Inc., Chicago, IL).
Results
The mean age (mean ± SD) of the women was 58.8
± 8.0 years. The participants (324 postmenopausal
women) were stratified into low (below or equal to
the median) and high (above the median) serum
IGF-1 groups. Table 1 shows the baseline charac-
teristics of the study participants, stratified by IGF-
1 groups. Women with high IGF-1 levels had sig-
nificantly higher alkaline phosphatase and osteo-
calcin levels than women with low IGF-1 levels.
No significant correlations were found between
IGF-1 and age, LDL cholesterol or HDL cholesterol,
fasting glucose, triglyceride, systolic or diastolic
blood pressure, weight, BMI, adiponectin, omentin-
1, or visfatin in bivariate analyses. However, IGF-1
levels were significantly correlated with circulating
alkaline phosphatase (r = 0.13, p = 0.013), osteocalcin
(r = 0.12, p = 0.017), and hs-CRP (r = −0.13, p =
0.012) levels in the participants (p<0.05). These cor-
relations persisted after further adjustment for age
and weight. Of the participants, 79 (24.4%) had type
2 diabetes mellitus; and 228 women (70.4%) had
metabolic syndrome (NCEP-ATP III criteria).
Inmultiple regression analyses adjusted for alkaline
phosphatase, osteocalcin, and hs-CRP, circulating
IGF-1 was significantly correlated with visfatin levels
(standardized β coefficient [β] = 0.13, partial correla-
tion coefficient [r] = 0.12, p = 0.028). The significant
positive correlation between serum IGF-1 and visfatin
levels remained after additional adjustments for age
and BMI (β = 0.12, r = 0.12, p = 0.025), metabolic
syndrome (β = 0.13, r = 0.12, p = 0.021), and type 2
diabetes mellitus (β = 0.13, r = 0.12, p = 0.026).
However, no significant correlation between IGF-1
and adiponectin or omentin-1 was found in multiple
regression models.
Discussion
Abundant evidence supports the anti-inflammatory,
antioxidant, and anti-atherosclerotic roles for IGF-1
(14–16). In addition, evidence that supports an inter-
esting connection between visfatin and inflammation
in cardiometabolic diseases is accumulating (10).
Although we found no correlation between IGF-1
and visfatin levels in bivariate analyses, the positive
significant correlation between these twomarkers was
revealed after adjustment for chronic low-grade
inflammation (hs-CRP) and bone formation biomar-
kers in multivariate regression models. The observed
significant association between IGF-1 and visfatin
levels in the current study raises this important ques-
tion whether a unique pathophysiological mechanism
exists behind the IGF-1 and visfatin correlation.
Unfortunately, studies on healthy adults in the
medical literature about IGF-1 in relation to visfatin
as an important proinflammatory marker are lacking.
However, in vitro studies conducted by Olarescu et al.
(24) revealed that IGF-1 promotes the inhibition of
nicotinamide phosphoribosyltransferase (NAMPT)/
visfatin expression during differentiation and in
mature adipocytes. Therefore, the authors suggested
that at least some of the known anti-atherosclerotic
actions may be mediated through the inhibition of
NAMPT/visfatin (24). In another in vitro study,
Yammani and Loeser (27) investigated the role of
NAMPT/visfatin in regulating IGF-1 function in
human articular chondrocytes isolated from normal
ankle cartilage. They found that the pretreatment of
chondrocytes with NAMPT/visfatin inhibited IGF-
Table 1. The general characteristics, including blood pressure,
anthropometric measurements, and the biochemical para-
meters of postmenopausal women, stratified by insulin-like





Age 59.2 ± 7.9 58.4 ± 7.7
Weight (kg) 67.7 ± 13.4 68.12 ± 12.8
Body mass index (kg/m2) 28.1 ± 4.9 28.5 ± 5.0
Systolic blood pressure
(mmHg)
127 ± 19 124 ± 20
Diastolic blood pressure
(mmHg)
79 ± 9 80 ± 24
Fasting blood glucose (mg/
dl)
119 ± 58 112 ± 47
Triglyceride (mg/dl) 119 ± 89 179 ± 102
Total cholesterol (mg/dl) 233 ± 45 238 ± 50
HDL-cholesterol (mg/dl) 40 ± 10 42 ± 11
LDL-cholesterol (mg/dl) 155 ± 41 160 ± 45
Alkaline phosphatase (U/L) 232 ± 78 258 ± 100**
Omentin (ng/mL)* 11 ± 3 12 ± 2
Adiponectin (µg/mL)* 11± 2 10 ± 2
Visfatin (ng/mL)* 2.6 ± 1.9 2.9 ± 1.9
CrossLaps (ng/mL)* 1.8 ± 1.6 1.6± 1.7
Osteocalcin (ng/mL)* 10 ± 1 12± 2**
hs-CRP (mg/L)* 1.9 ± 2.8 1.6 ± 2.5
Values are mean ± standard deviation
*Geometric mean ± standard deviation
**p < 0.05
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induced phosphorylation of signaling molecules,
including insulin receptor substrate-1 and the Akt
signaling pathway. They also demonstrated that the
stimulation of chondrocytes with NAMPT/visfatin
elicited a sustained phosphorylation of the extracellu-
lar signal-regulated kinase (ERK)/MAPK signaling
pathway, independent of IGF-1 receptor activation.
Although NAMPT/visfatin receptor for the activation
of the ERK/MAPKpathway is unknown, these in vitro
studies on human chondrocytes showed that
NAMPT/visfatin-induced increased ERK/MAPK
pathway results in decreased IGF-1 function (27).
Regarding the explanation for the observed positive
relationship of visfatin (as an atherosclerotic adipocy-
tokine) with IGF-1 (as an anti-atherosclerotic agent)
in multivariate analysis among postmenopausal
women, we hypothesized that the observed higher
circulating IGF-1-1 in higher visfatin levels might be
a physiological compensation and adaptation to pro-
tect against the NAMPT/visfatin-induced increased
ERK/MAPK pathway that blocks IGF-1 function.
In the current population-based study, the regres-
sionmodels for IGF-1 in relation to circulating visfatin
levels were adjusted for alkaline phosphatase, osteo-
calcin, and hs-CRP levels because we found that bone
formation markers and hs-CRP levels were signifi-
cantly correlated with IGF-1 levels in bivariate ana-
lyses. Overall, the significant correlation between IGF-
1 and circulating visfatin was elucidated after adjust-
ment for bone formation markers levels and chronic
low-grade inflammation, as important determinants
of circulating IGF-1 levels. The positive correlation
between IGF-1 and bone formation markers and the
inverse correlation between IGF-1 and CRP had been
reported in previous studies (28,31).
Low circulating IGF-1 levels are associated with
metabolic syndrome and its various components
(18), risk of glucose intolerance, type 2 diabetes melli-
tus (15,32,33), and the increased prevalence of obesity
(34). However, in the present study we demonstrated
that IGF-1 was significantly correlated with visfatin
levels when the logistic regressionmodels were further
adjusted for these confounding factors. Thus, our
findingsmay confirm this concept that IGF-1 is linked
with circulating visfatin beyond its relationship with
metabolic syndrome, type 2 diabetes, and obesity
measures.
In the current study, IGF-1 levels were not signifi-
cantly correlated with circulating adiponectin. The
medical literature is inconsistent in the correlation
between IGF-1 and adiponectin and shows conflicting
results. In 142 patients with heart failure, the log-
transformed IGF-1 axis values had a negative correla-
tion with the log-transformed serum adiponectin
levels (35). Similarly, Kanazawa et al. (20) reported a
significant inverse association between IGF-1 and adi-
ponectin levels in Japanese men with type 2 diabetes
independent of age, duration of diabetes, BMI, renal
function, and HbA1c. The authors suggested IGF-1
might suppress serum adiponectin levels (20).
However, a positive correlation between the IGF-1 z
score and adiponectin was observed among obese
nondiabetic women (19). This association remained
significant even after adjustment for age, BMI, insulin
sensitivity, and chronic inflammation indices (19). In
agreement with our results, no consistent association
between IGF-1 and adiponectin in healthy elderly
male Lebanese (36) and among postmenopausal
women (21) was reported. It seems that the conflicting
results may arise because the studies were conducted
in different categories of patients and serum levels of
IGF-1 and this adipocytokine may be influenced by
the accompanying pathological conditions (19).
The results of recent studies show sufficient evi-
dence indicating that omentin-1 may be a good adi-
pocytokine (19,20). Thus, omentin-1 may have a
positive correlation with the IGF-1 level. However,
we did not find a significant correlation between
serum omentin-1 and IGF-1 values. Since there is
no previously reported study regarding omentin-1 in
relation to IGF-1, future studies are required to clarify
and validate our results.
This study has several limitations. The present
cross-sectional study does not allow for inferring
causality from the observed correlation between
circulating IGF-1 and visfatin in multivariate ana-
lyses. Determining the temporal sequence of any
relationship between IGF-1 and this novel adipo-
cytokine requires longitudinal studies. Since we
assessed adipocytokines with single measurements,
the changes in the adipocytokines over time were
not reflected. Visfatin (9) and omentin-1 have
insulin-mimetic properties (5); however, we did
not adjust the regression models for measures of
insulin resistance including HOMA-IR. The find-
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ings from this postmenopausal cohort may not be
generalized to other sex and age groups. Finally, to
elucidate the underlying mechanism that regulates
adipocytokines and IGF-1 cascade, additional
inflammatory markers and cytokines should be
measured simultaneously because the transcription
and secretion of inflammatory cytokines such as
TNF-alpha, IL-1beta, and IL-6 visfatin are regu-
lated by visfatin (37).
In conclusion, the current study demonstrated that
postmenopausal women from the general population
exhibit a significant correlation between circulating
levels of IGF-1 and visfatin, independent of metabolic
syndrome, type 2 diabetes, and obesity measures.
Therefore, the findings of this first population-based
study confirm the results of recent in vitro studies
indicating that some anti-inflammatory and anti-
atherosclerotic effects of IGF-1 may be counteracted
by the visfatin effects.
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